| Oct 4 |
Spyre Therapeutics Announces Grants of Inducement Awards
|
| Oct 1 |
Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
|
| Oct 1 |
Spyre Therapeutics appoints Sheldon Sloan as CMO
|
| Oct 1 |
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
|
| Sep 10 |
Spyre Therapeutics to Participate in Upcoming Investor Conference
|
| Sep 6 |
Spyre Therapeutics files for $500M mixed securities shelf
|
| Aug 7 |
Spyre Therapeutics GAAP EPS of -$0.86 beats by $0.16
|
| Aug 7 |
Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 18 |
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
|
| Jun 18 |
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
|
